PET Brain imaging of α7-nAChR with [18F]ASEM
暂无分享,去创建一个
James Robert Brašić | A. Gjedde | D. Wong | A. Sawa | A. Horti | A. Nandi | N. Cascella | R. Freedman | H. Kuwabara | G. Wand | E. Weerts | N. George | H. Valentine | W. Kem | Jenny-Ann Phan | M. McDonald | Joshua Roberts | K. Kitzmiller | L. Gapasin | Lorena Gapasin | Michael A. McDonald | Noble George | Kelly Kitzmiller
[1] Ninon Burgos,et al. New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .
[2] Dean F. Wong,et al. The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM , 2018, NeuroImage.
[3] A. Gjedde,et al. Radioligand binding analysis of α2 adrenoceptors with [11C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding , 2017, Scientific Reports.
[4] S. Xie,et al. Effects of haloperidol, olanzapine, ziprasidone, and PHA‐543613 on spatial learning and memory in the Morris water maze test in naïve and MK‐801‐treated mice , 2017, Brain and behavior.
[5] M. Bloch,et al. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[6] H. Arias,et al. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats , 2017, Neuropharmacology.
[7] Richard E. Carson,et al. PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[8] M. Kassiou,et al. The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. , 2016, Current pharmaceutical design.
[9] A. Horti,et al. Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography. , 2015, Biochemical pharmacology.
[10] G. Knudsen,et al. Radiosynthesis and in vitro validation of (3)H-NS14492 as a novel high affinity alpha7 nicotinic receptor radioligand. , 2015, European journal of pharmacology.
[11] M. Kassiou,et al. The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia , 2015, CNS Drugs.
[12] Hiroto Kuwabara,et al. Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy , 2014, Molecular Imaging and Biology.
[13] R. Papke. Merging old and new perspectives on nicotinic acetylcholine receptors. , 2014, Biochemical pharmacology.
[14] Martin G Pomper,et al. 18F-ASEM, a Radiolabeled Antagonist for Imaging the α7-Nicotinic Acetylcholine Receptor with PET , 2014, The Journal of Nuclear Medicine.
[15] R. Freedman. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. , 2014, Annual review of medicine.
[16] S. Preskorn,et al. Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition: A Proof of Concept, Randomized Trial in Patients with Schizophrenia , 2014, Journal of psychiatric practice.
[17] M. Geyer,et al. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. , 2013, Biochemical pharmacology.
[18] A. Horti,et al. Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors. , 2013, Journal of medicinal chemistry.
[19] Anil Kumar,et al. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans , 2013, NeuroImage.
[20] James Robert Brašić,et al. Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers , 2013, Neuropsychopharmacology.
[21] D. Bertrand,et al. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia , 2013, Expert opinion on therapeutic targets.
[22] A. Lira,et al. Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain , 2012, Neuropsychopharmacology.
[23] C. Ahnallen,et al. The role of the &agr;7 nicotinic receptor in cognitive processing of persons with schizophrenia , 2012, Current opinion in psychiatry.
[24] D. Bertrand,et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.
[25] H. Geerts. α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease , 2012, Expert opinion on investigational drugs.
[26] R. Papke,et al. Investigation of the Molecular Mechanism of the α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator PNU-120596 Provides Evidence for Two Distinct Desensitized States , 2011, Molecular Pharmacology.
[27] H. Parri,et al. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. , 2011, Biochemical pharmacology.
[28] G. Knudsen,et al. 11C-NS14492 as a Novel PET Radioligand for Imaging Cerebral α7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements , 2011, The Journal of Nuclear Medicine.
[29] Stephen M. Smith,et al. A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.
[30] P. Brust,et al. Traumatic Brain Injury Elicits Similar Alterations in α7 Nicotinic Receptor Density in Two Different Experimental Models , 2011, NeuroMolecular Medicine.
[31] M. Bencherif,et al. Application of Alpha7 Nicotinic Acetylcholine Receptor Agonists in Inflammatory Diseases: An Overview , 2011, Pharmaceutical Research.
[32] D. Bertrand,et al. RG3487, a Novel Nicotinic α7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents , 2011, Journal of Pharmacology and Experimental Therapeutics.
[33] K. Gross,et al. Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse , 2010, Neuroscience.
[34] L. Price,et al. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature , 2010, Psychopharmacology.
[35] K. Hashimoto,et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography , 2009, Annals of nuclear medicine.
[36] D. Bertrand,et al. Nicotinic acetylcholine receptors: an overview on drug discovery , 2009, Expert opinion on therapeutic targets.
[37] J. Gold,et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.
[38] Nihal Ahmad,et al. Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] C. Gotti,et al. Neuronal nicotinic receptors: from structure to pathology , 2004, Progress in Neurobiology.
[40] Karl J. Friston,et al. Rigid Body Registration , 2003 .
[41] S. Scheff,et al. Time-dependent changes in rat brain cholinergic receptor expression after experimental brain injury. , 2002, Journal of neurotrauma.
[42] D. Woodruff-Pak,et al. Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. , 2002, Behavioral and cognitive neuroscience reviews.
[43] Mary Johnson,et al. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia , 2001, Journal of Chemical Neuroanatomy.
[44] S. Scheff,et al. Traumatic brain injury reduces hippocampal alpha7 nicotinic cholinergic receptor binding. , 2000, Journal of neurotrauma.
[45] William R Kem,et al. The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) , 2000, Behavioural Brain Research.
[46] H. Crawford,et al. Tobacco affects P50 sensory gating: Auditory event-related potential differences in heavy tobacco smokers and nonsmokers , 2000, NeuroImage.
[47] R. Kerwin,et al. Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia , 1999, Journal of neurochemistry.
[48] K. Blennow,et al. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. , 1999, Neuroreport.
[49] J P Changeux,et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. , 1999, Pharmacological reviews.
[50] B. Potter,et al. Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors , 1999, Neuropharmacology.
[51] Karl J. Friston,et al. Human Brain Function , 1997 .
[52] R. Freedman,et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.
[53] S. Arneric,et al. Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain. , 1994, European journal of pharmacology.
[54] G. Pearlson,et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.
[55] G. Sedvall,et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.
[56] P. Davies,et al. Postmortem stability of α-bungarotoxin binding sites in mouse and human brain , 1981, Brain Research.
[57] D. Bertrand,et al. Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia. , 2015, International review of neurobiology.
[58] Kenji Hashimoto,et al. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. , 2011, Current pharmaceutical design.
[59] J. Mikkelsen,et al. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. , 2010, Current pharmaceutical design.
[60] E. Albuquerque,et al. Mammalian nicotinic acetylcholine receptors: from structure to function. , 2009, Physiological reviews.
[61] R. Freedman,et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.
[62] Albert Gjedde,et al. Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. , 2005, International review of neurobiology.
[63] R. Papke,et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. , 2004, Molecular pharmacology.
[64] Nikos Makris,et al. Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.
[65] R Freedman,et al. Schizophrenia, sensory gating, and nicotinic receptors. , 1998, Schizophrenia bulletin.
[66] P. Davies,et al. Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. , 1981, Brain research.
[67] Derivatives of , 2022 .